JAMA Oncol: Phase 3 randomized trial | Sequentia chemotherapy vs simultaneous chemotherapy is used as an early postoperative ancillary treatment for cervical cancer

For early cervical cancer patients with adverse pathological factors, the role of chemotherapy as an afteroperative auxiliary treatment has not been agreed upon, except radiotherapy.
study aims to assess the clinical efficacy of SE CHEMOTHERAPY (SCRT) and simultaneous radiotherapy (CCRT) as postoperative aids for early cervical cancer compared to radiotherapy alone (RT).
study was a phase 3 randomized trial conducted in eight hospitals in China, recruiting patients with IB-IIA stage cervical cancer with adverse pathological factors after a cure hysterectomy.
randomly divided into 3 groups, receiving auxiliary RT, CCRT or SCRT.
end of the disease is a 3-year disease-free survival rate (DFS).
February 2008 -December 2018, a total of 1,048 patients (median age 48 (23-65) were recruited: 350 in the RT group, 345 in the CCRT group and 353 in the SCRT group.
the lowest rate of lymph nodes in the RT group (18.3%), the baseline demographics and disease characteristics of each treatment group were balanced.
SCRT was associated with a higher DFS rate than RT (3-year DFS rate: 90.0% vs. 82.0%; risk ratio of 0.52,95% CI 0.35-0.76); SCRT is still associated with a higher DFS rate than CCRT (90.0% vs 85.0%; 0.65, 0.44-0.96).
SCRT treatment also reduces the risk of cancer death compared to RT (five-year survival rate: 92.0% vs 88.0%; HR 0.58, 95% CI 0.35-0.95).
, however, there was no difference in risk of death from DFS and cancer in patients treated with CCRT or RT.
, the study showed that SCRT treatments improved DFS rates and reduced the risk of cancer death compared to CCRT for early cervical cancer patients.